Answers are grounded in this paper and cite their sources.
Clinical evaluation demonstrates anti-CD7 CAR-T cell activity against central nervous system leukemia in T-ALL/LBL, highlighting potential strategies to overcome refractory disease.
To the Editor, Central nervous system leukemia (CNSL) remains one of the most challenging manifestations of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL).Despite intensive therapy, outcomes after CNS relapse remain poor and treatment options are limited [1-3].CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated remarkable efficacy in R/R T-ALL/LBL, with complete remission (CR) rates approaching 90% [4][5][6][7].However, whether CD7 CAR-T cells can effectively traffic to and eradicate CNSL without excessive neurotoxicity remains poorly defined.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: